Biohaven Ltd. (NYSE:BHVN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Biohaven Ltd. (NYSE:BHVN) have been assigned an average rating of “Moderate Buy” from the eighteen ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, nine have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $22.5333.

A number of equities research analysts have recently weighed in on BHVN shares. TD Cowen lifted their target price on shares of Biohaven from $15.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. HC Wainwright decreased their price target on shares of Biohaven from $11.00 to $10.00 and set a “neutral” rating for the company in a research note on Wednesday, March 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Biohaven in a report on Monday, December 29th. Morgan Stanley cut their price objective on Biohaven from $26.00 to $21.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 6th. Finally, Citigroup increased their target price on Biohaven from $14.00 to $17.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd.

Biohaven Price Performance

Shares of Biohaven stock opened at $10.35 on Thursday. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of 4.59. The company has a market cap of $1.56 billion, a PE ratio of -1.49 and a beta of 1.34. The business has a 50 day moving average of $10.25 and a 200 day moving average of $11.53. Biohaven has a 52 week low of $7.48 and a 52 week high of $24.06.

Biohaven (NYSE:BHVN) last released its quarterly earnings results on Monday, March 2nd. The company reported ($1.21) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.01. As a group, equities research analysts forecast that Biohaven will post -8.9 earnings per share for the current year.

Hedge Funds Weigh In On Biohaven

A number of institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its stake in Biohaven by 113.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock valued at $36,000 after purchasing an additional 1,268 shares in the last quarter. PFS Partners LLC purchased a new stake in shares of Biohaven during the third quarter valued at approximately $60,000. EverSource Wealth Advisors LLC grew its holdings in shares of Biohaven by 178.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock valued at $46,000 after buying an additional 2,583 shares during the last quarter. IFP Advisors Inc increased its position in shares of Biohaven by 55.4% during the fourth quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock valued at $46,000 after acquiring an additional 1,450 shares in the last quarter. Finally, Arax Advisory Partners raised its holdings in Biohaven by 943.3% in the 4th quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock worth $55,000 after acquiring an additional 4,443 shares during the last quarter. Institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.